Synopsis
Synopsis
0
EU WC
0
KDMF
0
VMF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Cornutamine
2. Ergo Kranit
3. Ergo Sanol
4. Ergo-kranit
5. Ergodryl Mono
6. Ergomar
7. Ergostat
8. Ergotamine
9. Ergotamine Tartrate
10. Ergotamine Tartrate (2:1)
11. Ergotaminine
12. Gynergen
13. Lingraine
14. Mono, Ergodryl
15. Tartrate, Ergotamine
1. Ergotamine Tartrate
2. Ergotamine Bitartrate
3. 379-79-3
4. Schembl8045
5. Akos015897172
6. Ac-14836
Molecular Weight | 731.7 g/mol |
---|---|
Molecular Formula | C37H41N5O11 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 7 |
Exact Mass | 731.28025714 g/mol |
Monoisotopic Mass | 731.28025714 g/mol |
Topological Polar Surface Area | 233 Ų |
Heavy Atom Count | 53 |
Formal Charge | 0 |
Complexity | 1350 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Ergomar |
PubMed Health | Ergotamine Tartrate (By mouth) |
Drug Classes | Antimigraine |
Active Ingredient | Ergotamine tartrate |
Dosage Form | Tablet |
Route | Sublingual |
Strength | 2mg |
Market Status | Prescription |
Company | Rosedale Therapeutic |
2 of 2 | |
---|---|
Drug Name | Ergomar |
PubMed Health | Ergotamine Tartrate (By mouth) |
Drug Classes | Antimigraine |
Active Ingredient | Ergotamine tartrate |
Dosage Form | Tablet |
Route | Sublingual |
Strength | 2mg |
Market Status | Prescription |
Company | Rosedale Therapeutic |
Adrenergic alpha-1 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Agonists.)
Analgesics, Non-Narcotic
A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)
Oxytocics
Drugs that stimulate contraction of the myometrium. They are used to induce LABOR, OBSTETRIC at term, to prevent or control postpartum or postabortion hemorrhage, and to assess fetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (ABORTIFACIENTS). Oxytocics used clinically include the neurohypophyseal hormone OXYTOCIN and certain prostaglandins and ergot alkaloids. (From AMA Drug Evaluations, 1994, p1157) (See all compounds classified as Oxytocics.)
Serotonin Receptor Agonists
Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)
Vasoconstrictor Agents
Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2012-11-23
Pay. Date : 2012-11-08
DMF Number : 24782
Submission : 2011-03-23
Status : Active
Type : II
Certificate Number : CEP 2007-328 - Rev 04
Issue Date : 2025-01-13
Type : Chemical
Substance Number : 224
Status : Valid
Registration Number : 307MF10007
Registrant's Address : Ostravska 305/29, Komarov, 747 70 Opava, Czech Republic
Initial Date of Registration : 2025-01-09
Latest Date of Registration :
Available Reg Filing : ASMF |
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Registration Number : 220MF10122
Registrant's Address : Ostravska 305/29, Komarov, 747 70 Opava, Czech Republic
Initial Date of Registration : 2008-04-28
Latest Date of Registration :
Available Reg Filing : ASMF |
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-01-16
Pay. Date : 2013-12-02
DMF Number : 22932
Submission : 2009-07-06
Status : Active
Type : II
Certificate Number : R1-CEP 2008-291 - Rev 04
Issue Date : 2021-08-05
Type : Chemical
Substance Number : 224
Status : Valid
NDC Package Code : 55486-1581
Start Marketing Date : 2012-06-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3210
Submission : 1978-04-11
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3038
Submission : 1977-10-12
Status : Inactive
Type : II
NDC Package Code : 47848-001
Start Marketing Date : 2022-01-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100kg/100kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3358
Submission : 1978-10-13
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5765
Submission : 1985-03-27
Status : Inactive
Type : II
Certificate Number : R0-CEP 2001-255 - Rev 01
Issue Date : 2004-10-13
Type : Chemical
Substance Number : 224
Status : Withdrawn by Holder
NDC Package Code : 38779-0219
Start Marketing Date : 2013-04-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51927-0037
Start Marketing Date : 2002-07-19
End Marketing Date : 2027-03-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
97
PharmaCompass offers a list of Ergotamine Tartrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ergotamine Tartrate manufacturer or Ergotamine Tartrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ergotamine Tartrate manufacturer or Ergotamine Tartrate supplier.
PharmaCompass also assists you with knowing the Ergotamine Tartrate API Price utilized in the formulation of products. Ergotamine Tartrate API Price is not always fixed or binding as the Ergotamine Tartrate Price is obtained through a variety of data sources. The Ergotamine Tartrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CAFERGOT-1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CAFERGOT-1, including repackagers and relabelers. The FDA regulates CAFERGOT-1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CAFERGOT-1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CAFERGOT-1 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CAFERGOT-1 supplier is an individual or a company that provides CAFERGOT-1 active pharmaceutical ingredient (API) or CAFERGOT-1 finished formulations upon request. The CAFERGOT-1 suppliers may include CAFERGOT-1 API manufacturers, exporters, distributors and traders.
click here to find a list of CAFERGOT-1 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CAFERGOT-1 DMF (Drug Master File) is a document detailing the whole manufacturing process of CAFERGOT-1 active pharmaceutical ingredient (API) in detail. Different forms of CAFERGOT-1 DMFs exist exist since differing nations have different regulations, such as CAFERGOT-1 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CAFERGOT-1 DMF submitted to regulatory agencies in the US is known as a USDMF. CAFERGOT-1 USDMF includes data on CAFERGOT-1's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CAFERGOT-1 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CAFERGOT-1 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The CAFERGOT-1 Drug Master File in Japan (CAFERGOT-1 JDMF) empowers CAFERGOT-1 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the CAFERGOT-1 JDMF during the approval evaluation for pharmaceutical products. At the time of CAFERGOT-1 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of CAFERGOT-1 suppliers with JDMF on PharmaCompass.
A CAFERGOT-1 CEP of the European Pharmacopoeia monograph is often referred to as a CAFERGOT-1 Certificate of Suitability (COS). The purpose of a CAFERGOT-1 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of CAFERGOT-1 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of CAFERGOT-1 to their clients by showing that a CAFERGOT-1 CEP has been issued for it. The manufacturer submits a CAFERGOT-1 CEP (COS) as part of the market authorization procedure, and it takes on the role of a CAFERGOT-1 CEP holder for the record. Additionally, the data presented in the CAFERGOT-1 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the CAFERGOT-1 DMF.
A CAFERGOT-1 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. CAFERGOT-1 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of CAFERGOT-1 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CAFERGOT-1 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for CAFERGOT-1 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture CAFERGOT-1 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain CAFERGOT-1 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CAFERGOT-1 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of CAFERGOT-1 suppliers with NDC on PharmaCompass.
CAFERGOT-1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CAFERGOT-1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CAFERGOT-1 GMP manufacturer or CAFERGOT-1 GMP API supplier for your needs.
A CAFERGOT-1 CoA (Certificate of Analysis) is a formal document that attests to CAFERGOT-1's compliance with CAFERGOT-1 specifications and serves as a tool for batch-level quality control.
CAFERGOT-1 CoA mostly includes findings from lab analyses of a specific batch. For each CAFERGOT-1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CAFERGOT-1 may be tested according to a variety of international standards, such as European Pharmacopoeia (CAFERGOT-1 EP), CAFERGOT-1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CAFERGOT-1 USP).